Previous studies have suggested that proteasome inhibition by bortezomib kills cancer cells via blocking inducible I-κBα degradation and subsequently NF-κB activation [3], [4], [5], or preventing protein degradation of pro-apoptotic proteins such as Bax or p53 [6], [7]. Here, NFKB1 is linked to cancer.